Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Gliosarcoma × vandetanib × Clear all

Phase

Phase 1 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Carcinoma, Medullary 3 Thyroid Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 2b 1 Multiple Endocrine Neoplasia Type 2a 1 Multiple Endocrine Neoplasia 1 Gliosarcoma 1 Glioblastoma 1 Carcinoma, Renal Cell 1

Interventions

Temozolomide 21 Radiotherapy 14 Radiation 7 Bevacizumab 6 Carboplatin 5 Everolimus 4 Erlotinib Hydrochloride 4 Carmustine 4 temsirolimus 3 Vorinostat 3 Sirolimus 3 Radiotherapy, Conformal 3 Irinotecan 3 tipifarnib 2 atezolizumab 2 Surgical Procedures, Operative 2 Radiotherapy, Intensity-Modulated 2 Gefitinib 2 Fluorodeoxyglucose F18 2 Cilengitide 2 veliparib 1 vatalanib 1 vandetanib 1 terameprocol 1 tandutinib 1 romidepsin 1 plerixafor 1 picropodophyllin 1 pembrolizumab 1 pamiparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00441142 2019-03-05

Zactima

Dana-Farber Cancer Institute

Phase 1/2 Completed

119 enrolled 15 charts

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡